11 results on '"Sritara, P"'
Search Results
2. Herbal or traditional medicine consumption in a Thai worker population: pattern of use and therapeutic control in chronic diseases
- Author
-
Kanjanahattakij, Napatt, Kwankhao, Pakakrong, Vathesatogkit, Prin, Thongmung, Nisakron, Gleebbua, Yingampa, Sritara, Piyamitr, and Kitiyakara, Chagriya
- Published
- 2019
- Full Text
- View/download PDF
3. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
- Author
-
Fruchart, Jean-Charles, Santos, Raul D., Aguilar-Salinas, Carlos, Aikawa, Masanori, Al Rasadi, Khalid, Amarenco, Pierre, Barter, Philip J., Ceska, Richard, Corsini, Alberto, Després, Jean-Pierre, Duriez, Patrick, Eckel, Robert H., Ezhov, Marat V., Farnier, Michel, Ginsberg, Henry N., Hermans, Michel P., Ishibashi, Shun, Karpe, Fredrik, Kodama, Tatsuhiko, Koenig, Wolfgang, Krempf, Michel, Lim, Soo, Lorenzatti, Alberto J., McPherson, Ruth, Nuñez-Cortes, Jesus Millan, Nordestgaard, Børge G., Ogawa, Hisao, Packard, Chris J., Plutzky, Jorge, Ponte-Negretti, Carlos I., Pradhan, Aruna, Ray, Kausik K., Reiner, Željko, Ridker, Paul M., Ruscica, Massimiliano, Sadikot, Shaukat, Shimano, Hitoshi, Sritara, Piyamitr, Stock, Jane K., Su, Ta-Chen, Susekov, Andrey V., Tartar, André, Taskinen, Marja-Riitta, Tenenbaum, Alexander, Tokgözoğlu, Lale S., Tomlinson, Brian, Tybjærg-Hansen, Anne, Valensi, Paul, Vrablík, Michal, Wahli, Walter, Watts, Gerald F., Yamashita, Shizuya, Yokote, Koutaro, Zambon, Alberto, and Libby, Peter
- Published
- 2019
- Full Text
- View/download PDF
4. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study
- Author
-
Krittayaphong, Rungroj, Winijkul, Arjbordin, Methavigul, Komsing, Wongtheptien, Wattana, Wongvipaporn, Chaiyasith, Wisaratapong, Treechada, Kunjara-Na-Ayudhya, Rapeephon, Boonyaratvej, Smonporn, Komoltri, Chulalak, Kaewcomdee, Pontawee, Yindeengam, Ahthit, Sritara, Piyamitr, and for the COOL-AF Investigators
- Published
- 2018
- Full Text
- View/download PDF
5. Residual macrovascular risk in 2013: what have we learned?
- Author
-
Fruchart, Jean-Charles, Davignon, Jean, Hermans, Michel P, Al-Rubeaan, Khalid, Amarenco, Pierre, Assmann, Gerd, Barter, Philip, Betteridge, John, Bruckert, Eric, Cuevas, Ada, Farnier, Michel, Ferrannini, Ele, Fioretto, Paola, Genest, Jacques, Ginsberg, Henry N, Gotto, Antonio M, Hu, Dayi, Kadowaki, Takashi, Kodama, Tatsuhiko, Krempf, Michel, Matsuzawa, Yuji, Núñez-Cortés, Jesús Millán, Monfil, Carlos Calvo, Ogawa, Hisao, Plutzky, Jorge, Rader, Daniel J, Sadikot, Shaukat, Santos, Raul D, Shlyakhto, Evgeny, Sritara, Piyamitr, Sy, Rody, Tall, Alan, Tan, Chee Eng, Tokgözoğlu, Lale, Toth, Peter P, Valensi, Paul, Wanner, Christoph, Zambon, Alberto, Zhu, Junren, and Zimmet, Paul
- Subjects
Residual cardiovascular risk ,Atherogenic dyslipidaemia ,Type 2 diabetes ,Therapeutic options - Abstract
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R3i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R3i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R3i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptorα agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R3i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.
- Published
- 2014
- Full Text
- View/download PDF
6. Risk scores to predict decreased glomerular filtration rate at 10 years in an Asian general population.
- Author
-
Saranburut K, Vathesatogkit P, Thongmung N, Chittamma A, Vanavanan S, Tangstheanphan T, Sritara P, and Kitiyakara C
- Subjects
- Adult, Aged, Cohort Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Predictive Value of Tests, Renal Insufficiency, Chronic diagnosis, Risk Assessment trends, Thailand epidemiology, Time Factors, Asian People, Glomerular Filtration Rate physiology, Population Surveillance, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic physiopathology
- Abstract
Background: Asians have among the highest prevalence of chronic kidney disease (CKD) or end-stage renal disease in the world. A risk score capable of identifying high risk individuals at the primary care level could allow targeted therapy to prevent future development of CKD. Risk scores for new CKD have been developed in US general populations, but the impact of various risks factors for development of CKD may differ in Asian subjects. In this study, we aimed to develop risk models and simplified risk scores to predict the development of decreased glomerular filtration rate (GFR) at 10 years in an Asian general population using readily obtainable clinical and laboratory parameters., Methods: Employees of EGAT (The Electric Generating Authority of Thailand) were studied prospectively. Multivariable logistic regression models were used to assess risk factors and used to derive risk models and risk scores for developing decreased GFR at 10 years: Model 1 (Clinical only), Model 2 (Clinical + Limited laboratory tests), and Model 3 (Clinical + Full laboratory tests). The performance of the risk models or risk scores to predict incident cases with decreased GFR were evaluated by tests of calibration and discrimination., Results: Of 3186 subjects with preserved GFR (eGFR ≥60) at baseline, 271 (8.5%) developed decreased GFR (eGFR < 60) at 10 years. Model 1 (Age, sex, systolic blood pressure, history of diabetes, and waist circumference) had good performance (χ
2 = 9.02; AUC = 0.72). Model 2 (Age, Sex, systolic blood pressure, diabetes, glomerular filtration rate) had better discrimination (χ2 = 10.87, AUC = 0.79) than Model 1. Model 3 (Model 2+ Uric acid, Hemoglobin) did not provide significant improvement over Model 2. Based on these findings, simplified categorical risk scores were developed for Models 1 and 2., Conclusions: Clinical or combined clinical and laboratory risk models or risk scores using tests readily available in a resource-limited setting had good accuracy and discrimination power to estimate the 10-year probability of developing decreased GFR in a Thai general population. The benefits of the risk scores in identifying high risk individuals in the Thai or other Asian communities for special intervention requires further studies.- Published
- 2017
- Full Text
- View/download PDF
7. Relationship of vitamin D status and bone mass according to vitamin D-binding protein genotypes.
- Author
-
Nimitphong H, Sritara C, Chailurkit LO, Chanprasertyothin S, Ratanachaiwong W, Sritara P, and Ongphiphadhanakul B
- Subjects
- Absorptiometry, Photon methods, Adult, Biomarkers blood, Bone Density physiology, Calcifediol metabolism, Collagen Type I blood, Cross-Sectional Studies, DNA-Binding Proteins, Fasting blood, Female, Femur diagnostic imaging, Genotype, Hip diagnostic imaging, Humans, Lumbosacral Region diagnostic imaging, Male, Middle Aged, Peptide Fragments blood, Peptides blood, Procollagen blood, Statistics as Topic, Transcription Factors, Vitamin D metabolism, alpha-2-HS-Glycoprotein analysis, Bone Density genetics, Calcifediol blood, Vitamin D blood, Vitamin D-Binding Protein genetics
- Abstract
Background: Vitamin D-binding protein (DBP) may alter the biological activity of total 25-hydroxyvitamin D [25(OH)D]; this could influence on the effects of vitamin D in relation to bone mineral density (BMD) and fractures. Emerging data suggest that fetuin-A may be involved in bone metabolism. We aimed to investigate the influence of DBP gene polymorphism on the relationship of vitamin D status and fetuin-A levels to BMD and bone markers., Methods: This cross-sectional study was part of a health survey of employees of the Electricity Generating Authority of Thailand (1,734 healthy subjects, 72% male). Fasting blood samples were assayed for 25(OH)D, fetuin-A, N-terminal propeptides of type 1 procollagen (P1NP), C-terminal cross-linking telopeptides of type I collagen (CTx-I), and DBP rs2282679 genotypes. L1-L4 lumbar spine and femoral BMD were measured using dual-energy X-ray absorptiometry., Results: The DBP rs2282679 genotype distribution conformed to the Hardy-Weinberg equilibrium. There were no correlations between 25(OH)D levels and BMD and bone markers. But a trend of positive correlation was observed for the DBP genotypes with total hip BMD, and for the interaction between 25(OH)D and DBP genotypes with BMD at all femoral sites. We further analyzed data according to DBP genotypes. Only in subjects with the AA (common) genotype, 25(OH)D levels were positively related to BMD and bone markers, while fetuin-A was negatively related to total hip BMD, independently of age, gender and BMI., Conclusions: The interaction between vitamin D status, as measured by circulating 25(OH)D and DBP rs2282679 genotypes, modified the association between 25(OH)D and BMD and bone markers. Differences in DBP genotypes additionally influenced the correlation of fetuin-A levels with femoral BMD.
- Published
- 2015
- Full Text
- View/download PDF
8. Perception of hypertension management by patients and doctors in Asia: potential to improve blood pressure control.
- Author
-
Rahman AR, Wang JG, Kwong GM, Morales DD, Sritara P, and Sukmawan R
- Abstract
Background: Hypertension is one of the world's most common health conditions and is a leading risk factor for mortality. Although blood pressure can be modified, there is a large proportion of patients whose blood pressure remains uncontrolled. The aim of this study, termed Edvantage 360°, was to gain a deeper understanding of hypertension management in Asia from the perspective of patients and doctors, and to propose strategies to improve blood pressure control., Methods: Conducted in Hong Kong, Indonesia, Malaysia, the Philippines, South Korea, Taiwan, and Thailand, Edvantage 360° was a mixed-methods observational study that used both qualitative and quantitative elements: qualitative interviews and focus groups with patients (N = 110), quantitative interviews with patients (N = 709), and qualitative interviews with doctors (N = 85)., Results: This study found that, although there is good understanding of the causes and consequences of hypertension among Asian patients, there is a lack of urgency to control blood pressure. Doctors and patients have different expectations of each other and a divergent view on what constitutes successful hypertension management. We also identified a fundamental gap between the beliefs of doctors and patients as to who should be most responsible for the patients' hypertension management. In addition, because patients find it difficult to comply with lifestyle modifications (often because of a decreased understanding of the changes required), adherence to medication regimens may be less of a limiting factor than doctors believe., Conclusions: Doctors may provide better care by aligning with their patients on a common understanding of successful hypertension management. Doctors may also find it helpful to provide a more personalized explanation of any needed lifestyle modifications. The willingness of the doctor to adjust their patient interaction style to form a 'doctor-patient team' is important. In addition, we recommend that doctors should not attribute ineffectiveness of the treatment plan to patient non-adherence to medications, but rather adjust the medication regimen as needed.
- Published
- 2015
- Full Text
- View/download PDF
9. Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand.
- Author
-
Yamwong S, Permsuwan U, Tinmanee S, and Sritara P
- Abstract
Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel and ASA in patients with ACS based on a Thai cost database., Methods: A one-year decision tree and a long-term Markov model were constructed to estimate lifetime costs and quality-adjusted life years (QALYs). For the first year, data from PLATO (NCT00391872) were used to estimate the rate of cardiovascular events, resource use, and QALYs. For year 2 onwards, clinical effectiveness was estimated conditional on individual health states that occurred during the first year., Results: In the base-case analysis, the incremental cost-effectiveness ratio (ICER) with ticagrelor was 292,504 ($9,476) and 60,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability of ticagrelor being cost-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded clopidogrel., Conclusions: This health economic analysis provides cost effectiveness data for ticagrelor compared with both generic and branded clopidogrel in Thailand. Based on this analysis, it appears that ticagrelor is an economically valuable treatment for ACS compared with branded clopidogrel within the Thai context.
- Published
- 2014
- Full Text
- View/download PDF
10. The Association of vitamin D status and fasting glucose according to body fat mass in young healthy Thais.
- Author
-
Nimitphong H, Chailurkit LO, Chanprasertyothin S, Sritara P, and Ongphiphadhanakul B
- Abstract
Background: Existing inconclusive data on the relationship between vitamin D status and human glucose homeostasis suggests that other factors, such as adiposity, might influence this relationship. The present study aimed to investigate the association between 25-hydroxyvitamin D [25(OH)D] and fasting plasma glucose (FPG) in the context of different amounts of total body fat in a healthy community-based population in Bangkok, Thailand., Methods: This cross-sectional study was a part of health survey of employees of the Electricity Generating Authority of Thailand. There were 1,990 healthy subjects (72.8% male) in this study. Total body fat was measured by bioelectrical impedance analysis. Total serum 25(OH)D, 25(OH)D3 and 25(OH)D2 were measured by LC-MS/MS., Results: Age (r = 0.134, p < 0.001) and FPG (r = 0.089, p < 0.001) were positively correlated with 25(OH)D levels, while total body fat mass (r = -0.049, p = 0.03) were negatively correlated with 25(OH)D levels. 25(OH)D levels were higher in males than in females (65.0 ± 0.5 vs. 53.5 ± 0.5 nmol/L, p < 0.001). After controlling for age, gender and total fat mass, FPG was no longer correlated with 25(OH)D. However, when subjects were stratified according to fat-free mass tertiles and controlled for age and gender, there was a positive, although weak association between 25(OH)D levels and FPG (p = 0.01) in the lowest tertile., Conclusions: We therefore speculate that adiposity might influence the relationship of vitamin D status and FPG.
- Published
- 2013
- Full Text
- View/download PDF
11. The impact of different GFR estimating equations on the prevalence of CKD and risk groups in a Southeast Asian cohort using the new KDIGO guidelines.
- Author
-
Kitiyakara C, Yamwong S, Vathesatogkit P, Chittamma A, Cheepudomwit S, Vanavanan S, Hengprasith B, and Sritara P
- Subjects
- Adult, Asia, Southeastern ethnology, Cohort Studies, Female, Health Surveys, Humans, Male, Middle Aged, Prevalence, Renal Insufficiency, Chronic physiopathology, Risk Factors, Young Adult, Asian People ethnology, Glomerular Filtration Rate, Guidelines as Topic standards, Renal Insufficiency, Chronic ethnology
- Abstract
Background: Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group recommended that patients with CKD should be assigned to stages and composite relative risk groups according to GFR (G) and proteinuria (A) criteria. Asians have among the highest rates of ESRD in the world, but establishing the prevalence and prognosis CKD is a problem for Asian populations since there is no consensus on the best GFR estimating (eGFR) equation. We studied the effects of the choice of new Asian and Caucasian eGFR equations on CKD prevalence, stage distribution, and risk categorization using the new KDIGO classification., Methods: The prevalence of CKD and composite relative risk groups defined by eGFR from with Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI); standard (S) or Chinese(C) MDRD; Japanese CKD-EPI (J-EPI), Thai GFR (T-GFR) equations were compared in a Thai cohort (n = 5526), Results: There was a 7 fold difference in CKD3-5 prevalence between J-EPI and the other Asian eGFR formulae. CKD3-5 prevalence with S-MDRD and CKD-EPI were 2 - 3 folds higher than T-GFR or C-MDRD. The concordance with CKD-EPI to diagnose CKD3-5 was over 90% for T-GFR or C-MDRD, but they only assigned the same CKD stage in 50% of the time. The choice of equation also caused large variations in each composite risk groups especially those with mildly increased risks. Different equations can lead to a reversal of male: female ratios. The variability of different equations is most apparent in older subjects. Stage G3aA1 increased with age and accounted for a large proportion of the differences in CKD3-5 between CKD-EPI, S-MDRD and C-MDRD., Conclusions: CKD prevalence, sex ratios, and KDIGO composite risk groupings varied widely depending on the equation used. More studies are needed to define the best equation for Asian populations.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.